Conformationally constrained backbone cyclized peptide analogs

Details Conformationally constrained backbone cyclized peptide analogs Conformationally constrained backbone cyclized peptide analogs

1996-12-05

1999-02-23

Walsh, Stephen

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

Cyclic peptides

530314, 530311, 514 9, 514 10, 514 11, C07K 750

Patent

active

058745297

DESCRIPTION:

BRIEF SUMMARY
FIELD OF THE INVENTION

The present invention relates to conformationally constrained N.sup..alpha. backbone-cyclized peptide analogs cyclized via novel non-peptidic linkages, to novel N.sup..alpha.,.omega.-functionalized amino acid building units, to processes for the preparation of these backbone cyclized peptides and building units, to methods for using these peptide analogs and to pharmaceutical compositions containing same.


BACKGROUND OF THE INVENTION

As a result of major advances in organic chemistry and in molecular biology, many bioactive peptides can now be prepared in quantities sufficient for pharmacological and clinical utilities. Thus in the last few years new methods have been established for the treatment and therapy of illnesses in which peptides have been implicated. However, the use of peptides as drugs is limited by the following factors: a) their low metabolic stability towards proteolysis in the gastrointestinal tract and in serum; b) their poor absorption after oral ingestion, in particular due to their relatively high molecular mass or the lack of specific transport systems or both; c) their rapid excretion through the liver and kidneys; and d) their undesired side effects in non-target organ systems, since peptide receptors can be widely distributed in an organism.
Moreover, with few exceptions, native peptides of small to medium size (less than 30-50 amino acids) exist unordered in dilute aqueous solution in a multitude of conformations in dynamic equilibrium which may lead to lack of receptor selectivity, metabolic susceptibilities and hamper attempts to determine the biologically active conformation. If a peptide has the biologically active conformation per se, i.e., receptor-bound conformation, then an increased affinity toward the receptor is expected, since the decrease in entropy on binding is less than that on the binding of a flexible peptide. It is therefore important to strive for and develop ordered, uniform and biologically active peptides.
In recent years, intensive efforts have been made to develop peptidomimetics or peptide analogs that display more favorable pharmacological properties than their prototype native peptides. The native peptide itself, the pharmacological properties of which have been optimized, generally serves as a lead for the development of these peptidomimetics. However, a major problem in the development of such agents is the discovery of the active region of a biologically active peptide. For instance, frequently only a small number of amino acids (usually four to eight) are responsible for the recognition of a peptide ligand by a receptor. Once this biologically active site is determined a lead structure for development of peptidomimetic can be optimized, for example by molecular modeling programs.
As used herein, a "peptidomimetic" is a compound that, as a ligand of a receptor, can imitate (agonist) or block (antagonist) the biological effect of a peptide at the receptor level. The following factors should be considered to achieve the best possible agonist peptidomimetic a) metabolic stability, b) good bioavailability, c) high receptor affinity and receptor selectivity, and d) minimal side effects.
From the pharmacological and medical viewpoint it is frequently desirable to not only imitate the effect of the peptide at the receptor level (agonism) but also to block the receptor when required (antagonism). The same pharmacological considerations for designing an agonist peptidomimetic mentioned above hold for designing peptide antagonists, but, in addition, their development in the absence of lead structures is more difficult. Even today it is not unequivocally clear which factors are decisive for the agonistic effect and which are for the antagonistic effect.
A generally applicable and successful method recently has been the development of conformationally restricted peptidomimetics that imitate the receptor-bound conformation of the endogenous peptide ligands as closely as possible (Rizo and Gierasch, Ann. Rev. Biochem., 61:387, 1992). Inve

REFERENCES:
patent: 3988304 (1976-10-01), Garsky
patent: 4011182 (1977-03-01), Sarantakis
patent: 4054558 (1977-10-01), Garsky
patent: 4187217 (1980-02-01), Chipens et al.
patent: 4235886 (1980-11-01), Freidinger et al.
patent: 4310518 (1982-01-01), Freidinger et al.
patent: 5364851 (1994-11-01), Joran
patent: 5371070 (1994-12-01), Koerber et al.
Gilon et al., Biopolymers 31:745-750, 1991.
Krstenansky et al., Letters in Peptide Science, 1:229-2345, 1994.
Greiner et al., Pept. 1994, Proc.Eur. Pept. Symp. 23 rd, Meeting date 1994, 289-290, 1994.
Byk & Gilon, 1992, "Building units for N-backbone cyclic peptides. 1. Synthesis of protected N-(.omega.-aminoalkylene)amino acids and their incorporation into dipeptide units", J. Org. Chem. 57:5687-5692.
Charpentier et al., 1989, "Synthesis and binding affinities of cyclic and related linear analogues of CCK.sub.8 selective for central receptors", J. Med. Chem. 32:1184-1190.
Giannis & Kolter, 1993, "Peptidomimetics for receptor ligands--Discovery, development, and medical perspectives", Angew. Chem. Int. Ed. Engl. 32:1244-1267.
Gilon et al., 1992, "SAR studies of cycloseptide: Effects of cyclization and charge at position 6", Chem. Biol. Proc Am Pept Symp 12th. pp. 476-477.
Gilon et al., 1991, "Backbone cyclization: A new method for conferring conformational constraint on peptides", Biopolymers 31:745-750.
Hruby et al., 1990, "Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations", Biochem. J. 268:249-262.
Lamberts et al., 1990, "Somatostatin-receptor imaging in the localization of endocrine tumors", New England J. Med. 323:1246-1249.
Lamberts, 1988, "The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors", Endocrine Reviews 9:417-436.
Lymangrover & Keku, 1983, "Varying the duration of A23187 adminstration alters its effect on adrenal steroidogenesis", Life Sciences 34:371-377.
Mosberg et al., 1983, "Bis-penicillamine enkephalins possess highly improved specificity toward .delta. opioid receptors", Proc. Natl. Acad. Sci. USA 80:5871-5874.
Plotsky & Vale, 1985, "Patterns of growth hormone-releasing factor and somatostatin secretion into the hypophysical-portal circulation of the rat", Science 230:461-463.
Raynor et al., 1993, "Cloned somatostatin receptors: Identification of subtype-selective peptides and demonstation of high affinity binding of linear peptides", Mol. Pharmacol. 43:838-844.
Reisine & Bell, 1995, "Molecular biology of somatostatin receptors", Endocrine Reviews 16:427-442.
Reubi et al., 1995, "Multiple actions of somatostatin in neoplastic disease", TIPS 16:110-115.
Rizo et al., 1992, "Constrained peptides: Models of bioactive peptides and protein substructures", Annu. Rev. Biochem. 61:387-418.
Rodriguez et al., 1990, "Synthesis of cyclic analogues of cholecystokinin highly selective for central receptors", Int. J. Peptide Protein Res. 35:441-451.
Steranka et al., 1988, "Bradykinin as a pain mediator: Receptors are localized to sensory neurons, and antagonists have analgesic actions", Proc. Natl. Acad. Sci. USA 85:3245-3249.
Veber et al., 1984, "A super active cyclic hexapeptide analog of somatostatin", Life Sciences 34:1371-1378.
Veber et al., 1985, "The design of metabolically-stable peptide analogs", TINS pp. 392-396.
R.N. Zuckerman, 1993, "The chemical synthesis of peptidomimetic libraries", Current Opinion in Structural Biol. 3:580-584.

Affiliated with

Also associated with

Rating

Conformationally constrained backbone cyclized peptide analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Conformationally constrained backbone cyclized peptide analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conformationally constrained backbone cyclized peptide analogs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-308051